Cargando…
Double-blind, 12 month follow-up, placebo-controlled trial of mifepristone on cognition in alcoholics: the MIFCOG trial protocol
BACKGROUND: Increased levels of cortisol during acute alcohol withdrawal have been linked to cognitive deficits and depression. Preclinical research found that the glucocorticoid Type II receptor antagonist, mifepristone, prevented some of the neurotoxic effects of withdrawal and memory loss. Clinic...
Autores principales: | Donoghue, Kim, Rose, Abigail, Coulton, Simon, Milward, Joanna, Reed, Kylie, Drummond, Colin, Little, Hilary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4765152/ https://www.ncbi.nlm.nih.gov/pubmed/26912003 http://dx.doi.org/10.1186/s12888-016-0757-1 |
Ejemplares similares
-
Double-blind, placebo-controlled trial of mifepristone on cognition and depression in alcohol dependence
por: Donoghue, Kim, et al.
Publicado: (2020) -
Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial
por: Esteve, Josep Lluis Carbonell, et al.
Publicado: (2013) -
Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial
por: Chu, Justin J, et al.
Publicado: (2020) -
Mifepristone followed by misoprostol compared with placebo followed by misoprostol as medical treatment for early pregnancy loss (the Triple M trial): A double-blind placebo-controlled randomised trial
por: Hamel, Charlotte, et al.
Publicado: (2021) -
Effect of Mifepristone vs Placebo for Treatment of Adenomyosis With Pain Symptoms: A Randomized Clinical Trial
por: Che, Xuan, et al.
Publicado: (2023)